You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAlteplase
Accession NumberDB00009  (BIOD00050, BTD00050)
TypeBiotech
GroupsApproved
Description

Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells

Protein structureDb00009
Protein chemical formulaC2569H3928N746O781S40
Protein average weight59042.3000
Sequences
>Alteplase sequence
SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGG
TCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSA
LAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDC
YFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAK
PWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRS
PGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVH
KEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEAL
SPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGG
PLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP
Download FASTA Format
Synonyms
SynonymLanguageCode
t-PANot AvailableNot Available
t-plasminogen activatorNot AvailableNot Available
Tissue-type plasminogen activator precursorNot AvailableNot Available
tPANot AvailableNot Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cathflo Activaseinjection, powder, lyophilized, for solution2.2 mg/2mLintravenousGenentech, Inc.2001-09-04Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
ActivasekitGenentech, Inc.1987-11-13Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
ActivasekitGenentech, Inc.1987-11-13Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Cathflopowder for solution1 mginstillationHoffmann La Roche LimitedNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription ProductsNot Available
Over the Counter ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
CAS number105857-23-6
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available
Pharmacology
IndicationFor management of acute myocardial infarction, acute ischemic strok and for lysis of acute pulmonary emboli
PharmacodynamicsAlteplase binds to fibrin in a thrombus and converts the entrapped plasminogen to plasmin. It also produces limited conversion of plasminogen in the absence of fibrin.
Mechanism of actionAlteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionintravenous2.2 mg/2mL
Kit
Powder for solutioninstillation1 mg
Prices
Unit descriptionCostUnit
Activase 100 mg vial4779.71USD vial
Activase 50 mg vial2389.85USD vial
Cathflo activase 2 mg vial106.33USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point60 °CNovokhatny, V.V. et al., J. Biol. Chem. 266:12994-123002 (1991)
hydrophobicity-0.516Not Available
isoelectric point7.61Not Available
References
Synthesis ReferenceNot Available
General ReferenceNot Available
External Links
ATC CodesB01AD02S01XA13
AHFS Codes
  • 20:12.20
PDB Entries
FDA labelDownload (1.98 MB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabThrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.
AcenocoumarolThrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.
Acetylsalicylic acidMay enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.
Aminosalicylic AcidSalicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.
AnagrelideAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
ApixabanMay enhance the anticoagulant effect of Anticoagulants.
AprotininMay diminish the therapeutic effect of Thrombolytic Agents.
ArgatrobanMay enhance the anticoagulant effect of Anticoagulants.
Bismuth SubsalicylateSalicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.
BivalirudinMay enhance the anticoagulant effect of Anticoagulants.
CilostazolAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
CitalopramAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
Citric AcidThrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.
ClopidogrelAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
Dabigatran etexilateThrombolytic Agents may enhance the anticoagulant effect of Dabigatran Etexilate.
DalteparinThrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.
DanaparoidMay enhance the anticoagulant effect of Anticoagulants.
DesvenlafaxineAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
DicoumarolThrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.
DiflunisalAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
DipyridamoleAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
DuloxetineAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
Edetic AcidThrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.
EnoxaparinThrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.
EpoprostenolMay enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents.
EptifibatideAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
EscitalopramAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
Ethyl biscoumacetateThrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.
EtodolacAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
FenoprofenAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
FloctafenineAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
FluoxetineAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
FluvoxamineAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
Fondaparinux sodiumThrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.
HeparinThrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.
IbuprofenAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
IloprostMay enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents.
IndomethacinAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
KetoprofenAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
KetorolacAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
LevomilnacipranAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
Magnesium salicylateSalicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.
Mefenamic acidAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
MeloxicamAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
MilnacipranAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
NabumetoneAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
NadroparinMay enhance the anticoagulant effect of Anticoagulants.
NaproxenAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
NitroglycerinMay decrease the serum concentration of Alteplase.
OxaprozinAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
ParoxetineAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
PhenindioneThrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.
PhenprocoumonThrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.
PiroxicamAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
PrasugrelAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
RivaroxabanMay enhance the anticoagulant effect of Anticoagulants.
Salicylate-sodiumMay enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.
SalsalateSalicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.
SertralineAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
SulindacAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
SulodexideThrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.
Tiaprofenic acidAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
TicagrelorAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
TiclopidineAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
TinzaparinMay enhance the anticoagulant effect of Anticoagulants.
TirofibanAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
TolmetinAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
TreprostinilThrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.
VenlafaxineAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
VilazodoneAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
VorapaxarAgents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.
WarfarinThrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.
Food InteractionsNot Available

Targets

1. Plasminogen

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: activator

Components

Name UniProt ID Details
Plasminogen P00747 Details

References:

  1. Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23. Pubmed
  2. Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A: Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8. Pubmed
  3. Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70. Pubmed
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

2. Fibrinogen alpha chain

Kind: protein

Organism: Human

Pharmacological action: yes

Components

Name UniProt ID Details
Fibrinogen alpha chain P02671 Details

References:

  1. Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23. Pubmed
  2. Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A: Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8. Pubmed
  3. Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70. Pubmed

3. Urokinase plasminogen activator surface receptor

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Urokinase plasminogen activator surface receptor Q03405 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

4. Plasminogen activator inhibitor 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Plasminogen activator inhibitor 1 P05121 Details

References:

  1. Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on January 09, 2013 14:27